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Effects of Metformin and Vanadium on Leptin
Secretion from Cultured Rat Adipocytes
Wendy M. Mueller,* Kimber L. Stanhope,* Francine Gregoire,† Joseph L. Evans,‡ and Peter J. Havel*
Abstract
MUELLER, WENDY M., KIMBER L. STANHOPE,
FRANCINE GREGOIRE, JOSEPH L. EVANS, AND
PETER J. HAVEL. Effects of metformin and vanadium on
leptin secretion from cultured rat adipocytes. Obes Res.
2000;8:530–539.
Objective: We have reported that glucose utilization regu-
lates leptin expression and secretion from isolated rat adi-
pocytes. In this study, we employed two antidiabetic agents
that act to increase glucose uptake by peripheral tissues,
metformin and vanadium, as pharmacological tools to ex-
amine the effects of altering glucose utilization on leptin
secretion in primary cultures of rat adipocytes.
Research Methods and Procedures: Isolated adipocytes
(100 mL of packed cells per well) were anchored in a
defined matrix of basement membrane components (Matri-
gel) with media containing 5.5 mM glucose and incubated
for 96 hours with metformin or vanadium. Leptin secretion,
glucose utilization, and lactate production were assessed.
Results: Metformin (0.5 and 1.0 mM) increased glucose
uptake in the presence of 0.16 nM insulin by 37 6 10%
(p , 0.005) and 62 6 8% (p , 0.0001) over insulin alone,
respectively. Metformin from 0.5 to 5.0 mM increased
lactate production by 105 6 43% (p , 0.025) to 202 6 52%
(p , 0.0025) and at 1.0 and 5.0 mM increased the propor-
tional rate of glucose conversion to lactate by 78 6 18% (p
, 0.005) and 166 6 41% (p , 0.0025), respectively. At
concentrations less than 0.5 mM, metformin did not affect
leptin secretion, but at 0.5 mM, the only concentration that
significantly increased glucose utilization without increas-
ing glucose conversion to lactate, leptin secretion was mod-
estly stimulated (by 20 6 9%; p , 0.05). Concentrations
from 1.0 to 25 mM inhibited leptin secretion by 25 6 8%
(p , 0.005) to 89 6 4% (p , 0.0001). Across metformin
doses, leptin secretion was inversely related to the percent-
age of glucose taken up and released as lactate (r 5 20.74;
p , 0.0001). Vanadium (5 to 20 mM) increased glucose
uptake from 20 6 7% (p , 0.01) to 34 6 13% (p , 0.02)
and increased lactate production at 5 mM by 17 6 8% (p ,
0.025) and 10 mM by 61 6 20% (p , 0.02) but did not alter
the conversion of glucose to lactate. Vanadium (5 to 50 mM)
inhibited leptin secretion by 33 6 6% (p , 0.0025) to 61 6
8% (p , 0.0001).
Discussion: Both metformin and vanadium increase glu-
cose uptake and inhibit leptin secretion from cultured adi-
pocytes. The inhibition of leptin secretion by metformin is
related to an increase in the metabolism of glucose to
lactate. The inhibition by vanadium most likely involves
direct effects on cellular phosphatases. We hypothesize that the
effect of glucose utilization to stimulate leptin production in-
volves the metabolism of glucose to a fate other than anaerobic
lactate production, possibly oxidation or lipogenesis.
Key words: glucose uptake, lactate production,
anaerobic metabolism
Introduction
The adipocyte hormone, leptin, has a central role in the
regulation of food intake, energy expenditure, and body fat
stores (1,2). Circulating leptin concentrations are well cor-
related with adipose stores in humans (3–5) and animals
(5–7). However, leptin production is also acutely regulated
by nutritional status. For example, circulating leptin de-
creases after fasting (6,8–10) or energy restriction (11,12)
and increases after refeeding or overfeeding (9,13). These
changes of circulating leptin are disproportionate to the
relatively small changes of body fat. Although the regula-
tion of leptin expression and secretion is incompletely un-
derstood, changes of insulin secretion during fasting and
refeeding precede changes of circulating leptin concentra-
tions. There is a growing body of evidence that suggests a
role for insulin and glucose in mediating changes of circu-
lating leptin levels in vivo. For example, infusion of small
amounts of glucose to prevent the reductions of insulin and
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glucose during fasting in humans also prevents the decrease
in plasma leptin (8). Although insulin administration does
not acutely increase plasma leptin concentrations in human
subjects (14,15) increases have been reported after 4 to 6
hours during insulin infusions producing supraphysiological
(16,17) or physiological (18) increments of plasma insulin
levels. Similarly, prolonged hyperglycemia and hyperinsu-
linemia in response to extended glucose infusions increases
plasma leptin after several hours in nonhuman primates (7)
and human subjects (19). Lastly, leptin concentrations
increase 4 to 6 hours after high carbohydrate meals,
which induce large plasma insulin and glucose responses
in humans (20).
In vitro studies have shown that insulin increases leptin
expression and secretion in isolated rodent (21–23) and
human (15,24) adipocytes. It has not, however, been clear
whether the effect of insulin to increase leptin production is
a direct consequence of increased insulin signaling or might
be indirectly mediated by insulin’s actions on glucose me-
tabolism. Several in vivo studies have provided support for
the latter explanation. First, glucose administration induces
increases of ob mRNA expression, which are more closely
related to changes of plasma glucose than to plasma insulin
concentrations (25,26).
In addition, the decrease in plasma leptin during marked
caloric restriction in humans is better correlated with the
decrease in plasma glucose than with changes in insuline-
mia (11,12). Furthermore, we have found that low plasma
leptin levels in insulin-deficient streptozotocin diabetic rats
are acutely increased by insulin administration in proportion
to the degree of glucose lowering (27). Further support from
in vitro experiments for a role for adipose glucose utiliza-
tion in the regulation of leptin production is provided by our
recent report that increased glucose metabolism is an im-
portant mediator of insulin-stimulated leptin expression and
secretion. Blockade of glucose uptake or inhibition of gly-
colysis decreases ob gene expression and leptin secretion in
isolated rat adipocytes (28). However, glucose uptake, by
itself, only seems to be important in that glucose must first
be taken up by the adipocytes before it can be metabolized.
Rather than glucose uptake per se, the inverse relationship
observed, between the proportional conversion of glucose to
lactate and leptin secretion by isolated adipocytes (28),
suggests that a regulatory step for glucose metabolism to
mediate changes of leptin production involved the metabo-
lism of glucose to a point beyond the anaerobic metabolism
of glucose-derived pyruvate to lactate.
Metformin and vanadium are two antidiabetic agents,
which are able to enhance glucose uptake and utilization by
peripheral tissues (29,30). In the present study, we em-
ployed metformin and vanadium as pharmacological tools
to examine the effects of altering adipocyte glucose utiliza-
tion on leptin production in primary cultures of isolated
adipocytes. Glucose utilization, lactate production, and lep-
tin secretion were measured over 96 hours in isolated rat
adipocytes cultured in a basement membrane matrix that
maintains adipocyte differentiation.
Research Methods and Procedures
Materials
Media (Dulbecco’s modified Eagle’s medium [DMEM])
and fetal bovine serum (FBS) were purchased from Life
Technologies (Grand Island, NY). The media was supple-
mented with 6 mL each of minimal essential medium amino
acids, penicillin/streptomycin (5000 U/mL/5000 mg/mL),
and nystatin (10,000 U/mL; all from Life Technologies) per
500 mL of DMEM. Bovine serum albumin fraction V, 4-(2-
hydroxyethyl)-1-piperazineethansulfonic acid (HEPES), colla-
genase (Clostridium histolyticum, type II; specific activity, 456
U/mg), insulin, and metformin were purchased from Sigma
Chemical Co. (St. Louis, MO). Matrigel matrix was purchased
form Becton Dickinson (Franklin Lakes, NJ). Bis(maltolato)
oxovanadium(IV) (BMOV), an organified form of vanadium
(31), was a gift from Drs. John McNeill and Violet Yuen,
Department of Pharmaceutical Sciences, University of British
Columbia, Vancouver, BC, Canada. Six-well Falcon plates
were purchased from Fisher Scientific (Pittsburgh, PA). Nylon
filters were purchased from Tetko (Kansas City, MO).
Animals
Male Sprague-Dawley rats (3 to 6 months of age) were
obtained from Charles River (Wilmington, MA). Animals
were housed in hanging wire cages in temperature-
controlled rooms (22 °C) with a 12-hour light-dark cycle
and fed Purina chow diet (Ralston-Purina, St. Louise, MO)
and given deionized water ad libitum. Animal use and care
was in accordance with the National Institutes of Health
Guide for the Use and Care of Laboratory Animals and
conducted in facilities accredited by the American Associ-
ation for Accreditation of Laboratory Animal Care. The
study protocol was approved by the Administrative Animal
Use and Care Committee at University of California, Davis.
Methods
Cell Isolation/Preparation. Adipocytes were prepared
from epididymal fat pads from male Sprague-Dawley rats
weighing 300 to 600 g. Epididymal fat depots were
resected from halothane-anesthetized rats under aseptic
conditions, and adipocytes were isolated by collagenase
digestion by the Rodbell method (32) with minor
modifications as previously described (28). The
isolated adipocytes were then incubated for 30 minutes
at 37 °C before being plated and cultured on Matrigel-
coated plates.
Adipocyte Culture. Adipocytes were maintained in culture
anchored to a basement membrane matrix (Matrigel,
Becton Dickinson). Although all in vitro systems have
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inherent advantages and disadvantages, advantages of this
system compared with cultures containing free-floating
adipocytes are that the matrix simulates their normal
basement membrane attachment and that the cells are
maintained in close proximity to each other, allowing
direct cell-to-cell contact. Together the cell contact and
basement membrane attachment help to maintain dif-
ferentiation, because adipocytes have a strong tendency to
dedifferentiate in long term (.24-hour) culture. In
addition, the matrix and the small amount of serum in the
media both contain growth factors, which are also likely
to help maintain cell differentiation. Furthermore, the
adipocytes in this system are not exposed to toxic levels
of oxygen at the interface of the media and the incubator
atmosphere, as opposed to free-floating adipocytes which
aggregate at the surface of the media. An advantage of
the system over those containing minced adipose tissue is
that all of the cells in the culture are equally exposed to
the nutrients and the oxygen dissolved in the media.
Thus, although clearly different from the in vivo situation,
we believe that this system provides a more physiological
environment than most systems for maintaining
adipocytes in long term culture. In the case of the present
studies, the goal was to examine the direct actions of
metformin and vanadium on leptin production and
adipocyte metabolism. Therefore, the advantage of
employing in vitro experimentation for this purpose over
in vivo models was that it was possible to control
confounding variables, such as effects of these agents on
food intake, which would indirectly influence leptin
production via changes of insulin secretion (18,20).
Unlike an in vivo system, in this study the environment
surrounding the adipocytes within the individual wells of
each culture plate was identical with the exception of the
presence or absence and the concentration of metformin
or vanadium, allowing assessment of the direct effects of
the treatments.
In culturing each suspension, Matrigel was first thawed
on ice to a liquid and uniformly applied to the surface of
culture dishes (300 mL of Matrigel/35-mm well). After
the incubation period, 150 mL of the adipocyte
suspension (2:1 ratio of packed cells to media) were
plated on the liquid Matrigel matrix. Adipocytes from
each suspension were thoroughly mixed with a transfer
pipette before plating to insure that a similar number of
adipocytes with a similar size distribution were added to
the control and experimental wells for each suspension.
The warmth of the added cells and media caused the
Matrigel to gel around the adipocytes, effectively
anchoring them to the culture dish. After a 30-minute
incubation at 37 °C, 2 mL of warm culture medium was
added. The cells were maintained in an incubator at 37
°C for 96 hours with 6% CO2. Aliquots of adipocytes
from each animal were divided into wells, with the
different concentrations of either metformin or vanadium
(as detailed below). In each plate an appropriate con-
trol well contained adipocytes from the same animal.
Adipocytes were incubated with media (DMEM) con-
taining 5.5 mM (100 mg/dL) glucose plus 5% FBS at five
concentrations of Metformin (0.1, 0.25, 0.5, 1.0, 5.0, and
25.0 mM). A low basal concentration of insulin (0.16
nM) was added to the incubations performed with
metformin, because metformin is thought to act in part by
increasing insulin signaling (33,34). Vanadium was added
at four concentrations (5.0, 10.0, 20.0, and 50.0 mM) in
DMEM with 5.0 to 5.5 mM glucose and 1% FBS.
Adipocytes were cultured with vanadium without added
insulin, because vanadium action is considered to be
largely independent of insulin (35,36). To examine the
responses to insulin in the adipocytes obtained from each
adipocyte suspension in the vanadium experiments, a
separate well containing 1.6 nM insulin was included for
each suspension. In all experiments, aliquots of media
(300 mL, 15% of the media volume) were collected from
culture wells and replaced with fresh media containing
the appropriate concentrations of metformin or vanadium
at 24, 48, 72, and 96 hours.
Assays. Leptin concentrations in the medium were
determined with a sensitive and specific radioim-
munoassay for rat leptin (37) with reagents obtained from
Linco Research, St. Charles, MO. Glucose and lactate
were measured with a glucose analyzer (model 2300,
YSI, Yellow Springs, OH).
Data Analysis. The uptake of glucose was assessed by
measuring the concentration of glucose in the media in
each well before and at 24, 48, 72, and 96 hours of
incubation and calculating the decrease over 96 hours
after correcting for the amount of glucose that was
removed during each 24-hour media sampling and the
amount added by the replacement of fresh media (15% of
total volume). Lactate production was calculated as the
increase of media lactate at 24, 48, 72, and 96 hours by
correcting for the amount of lactate removed by sampling
and added with media replacement. To examine the
relationship between adipocyte carbon flux and leptin
secretion in adipocytes cultured with metformin or
vanadium, the amount of carbon released as lactate per
amount of carbon taken up as glucose over 96 hours was
calculated as lactate production/glucose utilization and
expressed as a percentage (28). Cumulative leptin
production was calculated as the change of media leptin
concentrations at 24, 28, 72, and 96 hours with correction
for the amount of leptin removed during sampling. The
area under the curve for leptin production between 0 and
96 hours was calculated by the trapezoidal method. The
experimental results from each adipocyte suspension
prepared from a single animal were analyzed in relation
to a control well from the same suspension. Given the
Metformin, Vanadium, and Leptin Secretion, Mueller et al.
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individual variation in leptin responses between animals
and/or suspensions, it was not appropriate to compare
means from control and treated adipocytes from different
animals and/or suspensions. Therefore, the means for all
the controls in the metformin (n 5 18) and vanadium
(n 5 14) experiments contain a larger sample size (n) of
animals and/or suspensions than all except the 1.0 mM
metformin dose, which was studied in every experiment.
Thus, when the number of wells with a particular
concentration of metformin or vanadium differed from the
total number of control wells (e.g., 0.5 mM metformin;
n 5 9), each result was compared only to that obtained in
a corresponding control well from the same suspension in
a pair-wise comparison. To examine the relationships
between the medium concentrations of metformin or
vanadium, glucose uptake, lactate production, and glucose
conversion to lactate, and leptin secretion, simple and
multiple linear regression analyses were performed with a
statistics software package (StatView for Macintosh,
Abacus Concepts, Inc., Berkeley, CA).
Because metformin exhibited toxic effects on adipocyte
metabolism at concentrations greater than 5.0 mM, results
from cultures incubated with metformin at concentrations
greater than 5.0 mM were not included in these analyses.
The relationship between lactate production from glucose
and leptin secretion was also examined within the control
groups alone. Data are expressed as means 1 SEM.
Results
Effects of Metformin
The effects of metformin on glucose uptake, lactate pro-
duction, and leptin secretion were examined. Metformin at
a concentration of 0.1 mM did not affect glucose uptake
compared with the corresponding control suspensions con-
taining insulin (0.16 nM) alone. At 0.25 mM, glucose up-
take was increased (%D 5 19 6 8%), but the effect was not
statistically significant perhaps due to the smaller number of
trials (n 5 5) performed at this concentration. Metformin
stimulated glucose uptake at concentrations of 0.5 mM
(137 6 10%, p , 0.005) and 1.0 mM (162 6 8%, p ,
0.0001) compared with that in the corresponding control
suspensions (Table 1, Figure 1). At 5.0 mM, glucose uptake
was not significantly different from control. Higher concen-
trations of metformin ($25.0 mM) markedly inhibited glu-
cose uptake most likely reflecting a toxic effect of met-
formin at these very high concentrations. Metformin had no
significant effect on lactate production at concentrations
lower than 0.5 mM but increased lactate production at
concentrations of 0.5 mM (1105 6 43% , p , 0.025), 1.0
mM (1186 6 31%, p , 0.0001), and 5.0 mM (1202 6
52%, p , 0.0025) vs. insulin alone (Table 1, Figure 1). At
concentrations of 25.0 mM, lactate production was mark-
edly inhibited (p , 0.0001), because glucose utilization was
almost completely suppressed. Concentrations of metformin
of 0.5 mM and below did not affect the proportional con-
version of glucose to lactate (Table 1). However, glucose
conversion to lactate was increased at a concentration of 1.0
mM, and this effect was marked at 5.0 mM with more than
twice the amount of glucose released as lactate (Table 1).
Although 1.0 mM metformin did increase mean glucose
uptake over control rates, a significantly larger proportion of
the glucose that was taken up was released as lactate. The
concentration of 0.5 mM was the only level of metformin
that induced a significant increase of glucose utilization
without increasing the proportion of glucose carbon re-
leased as lactate (Table 1).
At concentrations of metformin lower than 0.5 mM,
leptin secretion was unaffected. With metformin at 0.5 mM,
the area under the curve (AUC) for leptin secretion over 96
hours was significantly greater (120.5 6 9%, p , 0.05)
than control (Figure 2). Metformin inhibited leptin secretion
at concentrations of 1.0 mM (225 6 8%, p , 0.005), 5.0
mM (289 6 4%, p , 0.0001), and by 90% at toxic
concentrations of 25.0 mM (p , 0.0001) (Figure 2).
Within the 18 control wells, leptin secretion was
inversely related to the conversion of glucose to lactate
(r 5 20.61; p , 0.01). At metformin concentrations from
0 to 5.0 mM, leptin secretion was inversely proportional to
the log of the metformin concentration (r 5 20.53; p ,
0.0001), to lactate production (r 5 20.53; p , 0.0001), and
to the proportional conversion of glucose to lactate across
metformin doses (r 5 20.74; p , 0.0001)(Figure 3) but
was not related to glucose uptake (r 5 0.13; p 5 0.27) by
simple regression. By multiple regression analysis, leptin
secretion was inversely related to the conversion of glucose
to lactate (p , 0.0001) but not to the log of the metformin
concentration (p 5 0.91), lactate production (p 5 0.39), or
glucose uptake (p 5 0.62). Leptin secretion was only in-
creased over control by metformin at 0.5 mM, which was
also the only concentration that significantly increased glu-
cose uptake without shunting a greater proportion of the
glucose into lactate production (Table 1). A similar inverse
relationship (r 5 20.73; p , 0.0025) between leptin pro-
duction and anaerobic glucose metabolism to lactate was
observed in 32 control wells containing either no insulin or
a low insulin concentration of 0.16 nM (;20 mU/mL)
(Figure 4).
Effects of Vanadium
The effects of vanadium on glucose uptake, lactate pro-
duction, and leptin secretion were examined in adipocytes
cultured with concentrations of vanadium of 0 to 50 mM.
Vanadium at 5.0 mM (120 6 7%, p , 0.01), 10.0 mM
(138 6 12%, p , 0.02), and 20.0 mM (134 6 13%, p ,
0.02) increased glucose uptake, compared with rates of
glucose uptake in the corresponding control suspensions
(Table 2, Figure 5). The effect of vanadium at these con-
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centrations was comparable to that of insulin at 1.6 nM,
which increased glucose uptake by 38 6 8% (p ,
0.0001)(Table 2, Figure 5). Vanadium at 50.0 mM did not
significantly affect glucose uptake (%D 5 24 6 14%).
Vanadium at 5.0 mM increased lactate production by 1
17 6 8% (p , 0.025). Mean lactate production in the six
wells that served as controls for the 10.0 mM concentration
of vanadium was lower than average; however, lactate pro-
duction was increased in five of six corresponding experi-
mental wells. Thus, vanadium at 10 mM increased lactate
production by 61 6 20% (p , 0.02) despite absolute lactate
production being similar to the mean of the total 14 control
wells. At 20.0 and 50.0 mM, lactate production was not
significantly different from that of the control (Table 2).
Insulin at 1.6 nM increased leptin secretion over 96 hours
by 59 6 15% (p , 0.005) and the 0- to 96-hour AUC by
38 6 8% (p , 0.0001)(Figure 5). Leptin secretion was
unaffected by vanadium at a concentration of 5 mM. Higher
concentrations of 10, 20, and 50 mM consistently inhibited
leptin secretion over 96 hours by 233 6 6% (p , 0.0025),
253 6 7% (p , 0.0001), and 261 6 8% (p , 0.001),
respectively (Figure 6). Across vanadium concentrations,
leptin secretion at 96 hours was positively correlated with
glucose uptake (r 5 0.35; p , 0.02) and inversely related to
the log of the vanadium concentration (r 5 20.44; p ,
0.0001), to lactate production (r 5 20.30; p , 0.025), and
to the conversion of glucose to lactate (r 5 20.58; p ,
Table 1. Effects of metformin in the presence of 0.16 nM insulin on glucose uptake, lactate production, and the
percentage of glucose carbon taken up that was released as lactate by isolated rat adipocytes over 96 hours in
culture (mean 6 SEM)
[Metformin] (mM) 1
Insulin (0.16 nM)
Glucose uptake
(mmol) over 96 hours
Lactate production
(mmol) over 96 hours
Glucose to
lactate (%)
Control (n 5 18) 7.5 6 0.7 5.7 6 0.5 40.9 6 3.6
0.1 (n 5 4) 6.5 6 0.9 5.9 6 0.6 47.2 6 6.3
0.25 (n 5 5) 11.0 6 1.4 8.6 6 1.3 40.2 6 5.9
0.5 (n 5 9) 11.0 6 1.2† 9.5 6 1.2† 44.9 6 5.1
1.0 (n 5 18) 11.6 6 0.7‡ 14.4 6 0.9‡ 63.8 6 3.4*
5.0 (n 5 15) 8.3 6 0.6 14.4 6 1.0‡ 85.6 6 4.1‡
* p 5 0.01; † p 5 0.005; ‡ p 5 0.0005; vs. corresponding controls from the same adipocyte suspensions.
Figure 1. Glucose utilization (corrected for media sampling and
replacement) over 96 hours by isolated rat adipocytes in primary
culture with insulin at 0.16 nM and metformin at concentrations
from 0 to 25.0 mM.
Figure 2. Leptin secretion (corrected for media sampling and
replacement) over 96 hours by isolated rat adipocytes in primary
culture with insulin at 0.16 nM and metformin at concentrations
from 0 to 25.0 mM.
Metformin, Vanadium, and Leptin Secretion, Mueller et al.
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0.0001) (data not shown). By multiple regression analysis,
leptin secretion at 96 hours was more closely related to
glucose conversion to lactate (p , 0.0001) than to absolute
lactate production (p , 0.02) or the log of the vanadium
concentration (p , 0.005) and was not related to absolute
glucose uptake (p 5 0.22). Despite the relationship between
leptin secretion and the conversion of glucose to lactate
across vanadium concentrations, unlike with metformin, the
percentage of glucose released as lactate was not altered
by any concentration of vanadium (Table 2). In contrast,
insulin at 1.6 nM, which significantly decreased the
proportional conversion of glucose to lactate (i.e., anaer-
obic glucose metabolism) (Table 2), stimulated leptin
secretion (Figure 6).
Discussion
We have recently reported that insulin-mediated glucose
metabolism is an important factor regulating leptin expres-
sion and secretion in isolated rat adipocytes (28). Some
previous studies have shown that drugs in the thiazo-
lidinedione class, which are used in the treatment of type 2
diabetes, can inhibit leptin production in vitro and in vivo
(38,39). In the present study, we examined the effects of
metformin and vanadium, two other antidiabetic drugs
known to increase cellular glucose utilization, on leptin
secretion, glucose uptake, and lactate production in isolated
cultured rat adipocytes. Our goal was to use these com-
pounds as tools to examine their effects for altering adipo-
cyte glucose utilization on leptin secretion. Therefore, we
used concentrations within a range that were found to pro-
duce significant increases of adipocyte glucose uptake. Par-
ticularly in the case of metformin, these concentrations
(0.25 to 5.0 mM) were far above the range of plasma
concentrations (0.005 to 0.02 mM) observed in patients
treated with therapeutic doses of metformin (40). In fact, at
therapeutic concentrations, metformin seems to act primar-
ily to inhibit hepatic glucose production with limited, if any,
effects on peripheral glucose uptake (41–43). At therapeutic
concentrations, metformin generally has little direct effect
on glucose utilization in vitro (44,45). At concentrations
higher than those achieved in serum with therapeutic met-
formin administration, metformin stimulates glucose trans-
port by rat (46,47) and human adipocytes (48), and in rat
and human skeletal muscle (see reviews in 29,34,48,49). At
the cellular level, high concentrations of metformin increase
insulin receptor binding, along with tyrosine kinase activity,
glucose transport, and glycogen synthesis (33,34).
In the present study, metformin concentrations ranging
from 0.5 to 5.0 mM increased both glucose uptake and
lactate production. In addition to increasing absolute lactate
production, metformin at 1.0 and 5.0 mM increased the
percentage of glucose carbon that was metabolized to lac-
tate and released into the culture media by 80% to 170%. At
high concentrations of metformin (5 25.0 mM), both glu-
cose uptake and lactate production were markedly inhibited,
most likely due to a toxic effect of very high levels of
metformin on cellular metabolism. Metformin at 0.5 mM
modestly increased leptin secretion by ;20%.
Figure 3. Relationship between the percentage of glucose taken up
and released as lactate and leptin secretion over 96 hours by
adipocytes in primary culture with insulin (INS) at 0.16 nM and
metformin (MET) at concentrations from 0 to 5.0 mM. Leptin
secretion, glucose utilization, and lactate production are corrected
for media sampling and replacement.
Figure 4. Relationship between the percentage of glucose taken up
and released as lactate and leptin secretion over 96 hours by
adipocytes in primary culture in 32 control wells containing no
added insulin or insulin at a low concentration of 0.16 nM. Leptin
secretion, glucose utilization, and lactate production are corrected
for media sampling and replacement.
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Importantly, this was the only concentration of met-
formin tested that increased glucose uptake without shunt-
ing a greater proportion of glucose into lactate production.
In contrast, at concentrations of 1.0 mM and higher, leptin
secretion was modestly to markedly suppressed.
A significant proportion of glucose taken up by adipose
tissue is metabolized to lactate and released (50). At met-
formin concentrations # 5.0 mM, leptin secretion was in-
versely related to the amount of glucose taken up by the
adipocytes, converted to lactate, and released into the me-
dia. We have previously observed that the stimulation of
leptin secretion by insulin is associated not only with in-
creased glucose utilization, but with a decrease in the pro-
portional conversion of glucose to lactate (28), a finding that
was also observed within the control groups in the present
study (Figure 4). Thus, when lactate production is increased,
less carbon derived from glucose is available to enter the
tricarboxylic acid cycle either for oxidation or use in de
novo lipogenesis. Together, these data suggest that it is not
glucose uptake, per se, but its metabolism beyond pyruvate
and lactate in the adipocyte that is involved in the action of
glucose to stimulate leptin secretion. Thus, the anaerobic
metabolism of glucose does not stimulate leptin production.
The entry of glucose into the hexosamine biosynthetic path-
way and the production of UDP-glucosamine have been
suggested as a mechanism by which glucose utilization can
Table 2. Effects of insulin (1.6 nM) or vanadium on glucose uptake, lactate production, and the percentage
of glucose carbon taken up that was released as lactate by isolated rat adipocytes over 96 hours in culture
(mean 6 SEM)
[Vanadium] (mM);
no insulin added
Glucose uptake
(mmol) over 96 hours
Lactate production
(mmol) over 96 hours
Glucose to
lactate (%)
Control (n 5 14) 6.8 6 0.5 5.6 6 0.6 42.4 6 4.3
1.6 nM Ins (n 5 14) 9.4 6 0.9§ 5.7 6 0.7 33.0 6 3.5‡
5.0 (n 5 12) 7.8 6 1.1§ 5.7 6 0.6* 40.5 6 4.7
10.0 (n 5 6) 8.2 6 1.3‡ 5.2 6 0.8† 36.0 6 6.5
20.0 (n 5 12) 8.7 6 1.2‡ 6.3 6 0.6 41.6 6 5.0
50.0 (n 5 13) 6.9 6 1.02 4.9 6 0.5 53.3 6 9.4
* p 5 0.05; † p 5 0.02; ‡ p 5 0.0025; § p 5 0.0005; vs. corresponding control wells from the same adipocyte suspensions.
Figure 5. Glucose utilization (corrected for media sampling and
replacement) over 96 hours in by isolated rat adipocytes in primary
culture with vanadium at concentrations from 0 to 50.0 mM or with
insulin at 1.6 nM.
Figure 6. Leptin secretion (corrected for media sampling and
replacement) over 96 hours by isolated rat adipocytes in primary
culture with vanadium at concentrations from 0 to 50.0 mM or with
insulin at 1.6 nM.
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stimulate leptin production in adipose tissue (51). However,
our results indicate that glucose can be metabolized to
lactate, a point well beyond where glucose enters the hex-
osamine pathway, without stimulating leptin production.
Therefore, if the hexosamine pathway were to be the sole
mechanism by which glucose regulates leptin production,
one would need to postulate that either anaerobic glucose
metabolism and/or metformin itself, have an inhibitory
effect on glucose entry into this pathway. The results of
the present study suggest that it is more likely that the
effect of glucose metabolism to stimulate leptin produc-
tion involves glucose oxidation and/or the production of
lipogenic precursors.
Metformin at 0.1 and 0.25 mM did not effect glucose
metabolism or leptin secretion. Thus, metformin at thera-
peutic levels is unlikely to affect leptin production in vivo.
Of the concentrations of metformin tested in this study, only
0.5 mM increased glucose uptake without shunting a larger
proportion of the glucose into lactate. As previously dis-
cussed, this was the only concentration of metformin that
had effects on glucose metabolism that did not inhibit leptin
secretion, and, in fact, leptin secretion was modestly in-
creased at 0.5 mM. Thus, only when glucose uptake and its
metabolism beyond lactate were simultaneously increased,
did we observe an increase, and not an inhibition, of leptin
secretion. Therefore, it seems that only within a very narrow
concentration range is metformin able to have a net effect to
increase glucose uptake as well as its metabolism beyond
lactate in isolated adipocytes. Accordingly, the effects of
metformin to inhibit leptin secretion at most concentrations
examined is likely to be a result of its effects to direct
pyruvate metabolism into lactate and away from other po-
tential pathways for pyruvate metabolism such as oxidation
or lipogenesis.
The use of vanadium-containing compounds in the treat-
ment of diabetes has been widely investigated in animals
(52,53), and a few clinical trials have been conducted in
human patients (54,55). A compound structurally similar to
the form of organified vanadium used in this study (BMOV)
has recently entered Phase 1 clinical trials. To our knowl-
edge, the present study is the first report examining the
effects of a vanadium compound on leptin production in
vivo or in vitro.
Vanadium stimulated glucose uptake at concentrations up
to 20 mM, whereas glucose uptake was not affected by a
concentration of 50 mM. Lactate production was modestly
increased at the lower concentrations of vanadium. We
found that vanadium at a low concentration of 5.0 mM did
not affect leptin production, however, concentrations of
10.0 mM and higher inhibited leptin secretion from isolated
adipocytes by 30% to 60%. Although the amount of leptin
secreted was inversely proportional to the percentage con-
version of glucose to lactate across the concentrations of
vanadium tested, this relationship was significantly weaker
than that observed across metformin concentrations.
Furthermore, the proportion of glucose taken up and
released as lactate was unaffected by vanadium at any
concentration. Thus, in contrast to what was observed with
metformin, the ability of vanadium to inhibit leptin secre-
tion seems to be independent of any effects on glucose
metabolism or lactate production, most likely because it
does not increase the proportion of glucose fluxing into
anaerobic metabolism.
The observed effects of vanadium result from one or
more of the multiple known biological actions of vanadium
in cells. These include the inhibition of protein tyrosine
phosphatases and the activation of cytosolic protein-
tyrosine kinases, resulting in the alteration of cellular ty-
rosine phosphorylation content (30,56). Vanadium has also
been shown to exert direct inhibitory effects on a number of
other cellular enzymes, including acid, alkaline, and dual-
function phosphatases, ATPases, glucose-6-phosphatase,
and fructose-2,6-bisphosphatase (30,55). At high concentra-
tions, vanadium might exert some toxic effects on the cells,
an effect which could underlie the lack of effect of the
highest concentration of vanadium to stimulate glucose
uptake, as well as the inhibition of leptin production at the
two highest concentrations examined. In particular, the
effects of vanadium to inhibit the activity of one or more
enzymes involved in cellular energy metabolism could
both inhibit leptin production and, at high concentrations,
impair the ability of the cell to utilize energy derived
from glucose metabolism.
In vanadium-treated animals, plasma vanadium concen-
trations have been estimated to be in the 10 to 20 mM range
and in human clinical trials in the 1 to 5 mM range (53).
Although it is unlikely based on the present results that the
concentration of vanadium achieved in humans would be
sufficient to affect leptin production, previous human stud-
ies employed low doses of vanadyl sulfate or sodium meta-
vanadate, which are molecular forms that exhibit poor
bioavailability. The potential effects on leptin secretion of
the more readily absorbed forms of vanadium, such as the
organified vanadium compound (BMOV) used in
the present study (31), should therefore be considered.
In summary, both metformin and vanadium inhibit leptin
secretion from primary cultures of rat adipocyte at concen-
trations that significantly increase glucose utilization. The
inhibition of leptin production by metformin, but not by
vanadium, is related to an increased conversion of glucose
to lactate (i.e., anaerobic metabolism). This effect of met-
formin, coupled with our previous findings (28), suggests
that the effect of glucose utilization to stimulate leptin
production is not mediated by glucose uptake per se but
involves the metabolism of glucose beyond pyruvate to a
fate other than lactate, possibly oxidation or lipogenesis.
Thus, metformin is a useful tool for examining the effects of
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increasing anaerobic glucose metabolism. Further research,
including examination of the potential roles of glucose
oxidation and lipogenesis, needs to be conducted to deter-
mine the precise biochemical and molecular mechanisms by
which glucose metabolism regulates leptin production.
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